Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

No Thumbnail Available

Date

2021

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Randomised Controlled Trials, Phase II and III Clinical Trials, Immune checkpoint inhibitors

Citation

URI

http://hdl.handle.net/11727/7216

Collections

Tıp Fakültesi / Faculty of Medicine
Wos İndeksli Yayınlar Koleksiyonu
Wos Kapalı Erişimli Yayınlar

Endorsement

Review

Supplemented By

Referenced By